Results for: C_TS4CO_2023日本語出題内容 🐇 C_TS4CO_2023日本語全真模擬試験 🥗 C_TS4CO_2023日本語試験勉強書 🤟 ➡ www.goshiken.com ️⬅️で✔ C_TS4CO_2023日本語 ️✔️を検索して、無料で簡単にダウンロードできますC_TS4CO_2023日本語試験参考書

The woes of neurology drug development: Eli Lilly

November 21, 2012

…The difficulties of developing new therapies for neurological disorders is well documented (see CNS drug development: a pipeline of problems, Neurosens, November 9, 2011). The most recent case in point: Eli Lilly, which has had a tough summer with two of its late-stage drugs. Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…

Testing the new NIA-AA criteria for MCI

November 21, 2012

…A European group has examined the risk of progression to Alzheimer’s disease for the four MCI subgroups outlined in the National Institute on Aging-Alzheimer’s Association (NIA-AA) recommendations (Guo et al. Eur Arch Psychiatry Clin Neurosci 2012; epublished August 30, 2012). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…

GDS recommended for depression screening in PD

November 21, 2012

The Methods of Optimal Depression Detection in Parkinson’s Disease (MOOD-PD) study has reviewed patient self-report scales, concluding that the 30-item Geriatric Depression Scale (GDS) is the most efficient tool to screen for clinical depression in PD patients (Williams et al. Neurology 2012;78:998-1006). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter…

FDA delays review of alemtuzumab

November 7, 2012

The U.S. Food and Drug Administration has issued a Refuse to File (RTF) letter in response to Genzyme’s application for approval of alemtuzumab (Lemtrada) as a treatment for MS. The RTF letter requires that Genzyme reorganize the data presented and resubmit its application. Although no new data are required, the RTF is expected to delay any approval of the drug in MS by at least six months. The drug is currently under review by the European Medic…

Aubade for Aubagio: FDA approves teriflunomide in RRMS

October 24, 2012

…The U.S. Food and Drug Administration has approved the use of oral teriflunomide (Aubagio) 7 or 14 mg/day for the treatment of relapsing forms of MS. The drug was submitted for FDA review in October 2011. The drug has not yet been approved by Health Canada. Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…